Navigation Links
Doctors Treat Early Heart Attacks Before Labs Could Confirmation It

An international found that doctors do a good job of aggressively treating the early stages of heart attacks – even before laboratory tests confirm// the diagnosis. The study involved 467 hospitals spread across 12 countries.

“There has always been a concern that patients may be treated less aggressively when they present with heart attack symptoms before laboratory tests are able to confirm the diagnosis,” said Chadwick Miller, M.D., lead author and an emergency medicine physician at Wake Forest University School of Medicine. “But these findings suggest doctors are doing an appropriate job of aggressively treating these patients.”

Results from the research, which included more than 8,000 patients, are reported on-line in the European Heart Journal and will appear in a future print issue.

Laboratory testing is one tool used by doctors to confirm whether a patient is experiencing a heart attack. The tests measure levels of the protein troponin, which increase when there is damage to the heart muscle. However, it can take six to eight hours after symptoms begin for these markers to increase.

“These tests are also used by doctors to determine which therapies would benefit the patient the most,” said Miller. “Those with elevated markers are at higher risk, and more aggressive treatments are warranted. But, in patients who come to the emergency department immediately after their symptoms begin, it can be difficult to determine if they are having a heart attack. This uncertainty could lead to delay in treatment.”

The study compared results among three groups of patients: those with initially normal levels of troponin that became elevated within the next 12 hours – and were considered to be having an “evolving” heart attack; those whose markers were elevated at the time of the evaluation and were diagnosed with a heart attack; and those whose markers did not become elevated within 12 hours.

“We wanted to determine if these patients with early symptoms were being treated the same as patients who were known to be having a heart attack, or if the doctors were waiting for elevated heart markers before beginning treatment,” said Miller. “Our findings suggest that doctors were treating both of these high-risk patient groups the same and were not waiting for the heart markers to elevate.”

The results showed that in both groups that had heart attacks, doctors treated patients with aspirin and other blood-thinning medications. The groups also had similar rates of angioplasty, a procedure to open blocked arteries, and surgery to “bypass” blocked arteries.

Miller said the results suggest that doctors are using other immediately available data, such as information from the patient's history and electrocardiogram, to make treatment decisions.

The researchers also found that those patients who were having an “evolving” heart attack were 19 percent less likely to die or have a second heart attack within 30 days than patients who were immediately diagnosed with a heart attack. Although the exact reason for this finding cannot be determined from this research, this finding could be due to earlier treatment, said Miller. The patients with “evolving” heart attacks came to the emergency department a median of 1.7 hours after their symptoms developed, compared to 4 hours for those whose heart attack markers had already increased.

Of the 8,312 patients in the study, 66 percent were diagnosed with a heart attack at enrollment, 20 percent had an “evolving” heart attack that showed up on lab tests within 12 hours and 13 percent of participants didn’t have elevated markers within 12 hours.

The research was an analysis of a larger trial, the Superior Yield of the New strategy of Enoxaparin, Revascularization, and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) trial. The study included patients who met two of the following criteria: at least 60 years old, elevated heart markers and an electrocardiogram test that indicated a possible heart attack.

ource-Newswise
SRM/B
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Doctors needed urgently in Gujarat
3. Doctors operate upon patients in candlelight- latest from the quake scene
4. Doctors at risk- the ugly side of the noble profession
5. Doctors advice early anemia tests
6. Emphasis to ban Drugs ads by Doctors
7. Doctors not to accept gifts from drug companies
8. Gene testing kit specific for Doctors
9. Doctors warned of fluoride toxicity
10. Doctors decisions are affected by fear of lawsuits- says a study
11. Bihar High Court Intervenes To End Doctors Strike
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... 31, 2016 , ... Phynd Technologies, Inc. announced recently the signing of three ... and Shore Medical Center – Somers Point, NJ. The new clients range in bed ... the breadth of Phynd’s solution and its interoperability. , Houston Methodist is a leading ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview ... and broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance ... she calls the country’s “modern medical money maelstrom.” , During the interview with ...
(Date:5/31/2016)... ... ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree from ... where he graduated in the top ten percentile of his class. Dr. Ditta has ... has been a member in good standing for thirty years in the American Dental ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet ... to the healthcare industry, The University of Scranton is adding a Certificate in ... to a career in rapidly growing field of healthcare information. , Healthcare ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Super Powder, a ... to on the go individuals and dedicated athletes, continues to transform the nutritional supplement ... with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology: